ijms-logo

Journal Browser

Journal Browser

Cerebrovascular Diseases: Mediators of the Capillary No-Reflow Phenomenon After Acute Ischemic Stroke

Special Issue Editor


E-Mail Website
Guest Editor
1. Hungarian Centre of Excellence for Molecular Medicine—University of Szeged Cerebral Blood Flow and Metabolism Research Group, Szeged, Hungary
2. Department of Cell Biology and Molecular Medicine, Albert Szent-Györgyi Medical School and Faculty of Science and Informatics, University of Szeged, Szeged, Hungary
Interests: theoretical medicine

Special Issue Information

Dear Colleagues,

The capillary no-reflow phenomenon refers to the inadequate cerebral perfusion that develops despite successful recanalization in the AIS therapy. Even though futile reperfusion is often associated with an unfavorable clinical diagnosis, our understanding of the underlying mechanisms remains limited. The scope of our Special Issue is to address the latest observations and opinions on the mechanisms behind the capillary no-reflow phenomenon after acute ischemic stroke (AIS). We aim to summarize (i) the already known and (ii) suspected mediators of microvascular constriction in the sub-acute phase of AIS. We will focus on the roles of cell specific prostaglandins, eicosatetraenoic acids and vasoactive ions in the development of the capillary no-reflow.

Dr. Ákos Menyhárt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • capillary
  • acute ischemic stroke
  • cerebrovascular
  • no-reflow

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 828 KiB  
Review
Copeptin as a New Blood-Based Marker for Differential Diagnosis in Stroke Patients
by Antonia Ioana Vasile, Sorin Tuță, Cristina Tiu and Corin Badiu
Int. J. Mol. Sci. 2025, 26(11), 5328; https://doi.org/10.3390/ijms26115328 - 1 Jun 2025
Viewed by 447
Abstract
Diagnosis in stroke patients is based mainly on clinical and radiological findings; therefore, there is a need for serological markers that can orient the clinician. Copeptin is a new blood marker for diagnosis and prognosis in several neurological conditions, such as ischemic stroke, [...] Read more.
Diagnosis in stroke patients is based mainly on clinical and radiological findings; therefore, there is a need for serological markers that can orient the clinician. Copeptin is a new blood marker for diagnosis and prognosis in several neurological conditions, such as ischemic stroke, hemorrhagic stroke, aneurysmal subarachnoid hemorrhage, and multiple sclerosis. The aim of our study was to highlight the diagnostic value of copeptin in differentiating between stroke subtypes and stroke mimics. We performed a literature review by searching the PubMed and Scopus databases for papers with the following keywords: “stroke AND copeptin AND differential”. The PRISMA criteria were used. We identified 29 papers that met the criteria. We analyzed only original research articles, excluding reviews and only including those in English. Some studies did not find any significant differences between cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage, but one study demonstrated significant correlations. All studies agreed that copeptin levels can help in differentiating stroke patients from stroke-free patients. Copeptin levels were correlated with prognostic scales For stroke mimics, copeptin levels were extremely broad and for vestibular disorders; it was shown that a normal level of copeptin excludes stroke. Copeptin is a new blood marker that can help clinicians in the acute neurological field. It may help in diagnosing stroke, in differentiating between stroke subtypes and stroke mimics, and in evaluating the prognosis of these patients, but further studies are needed. Full article
Show Figures

Figure 1

Back to TopTop